G-CSF-primed bone marrow as a source of stem cells for allografting: revisiting the concept

Deotare, U; Al-Dawsari, G; Couban, S; Lipton, J H
September 2015
Bone Marrow Transplantation;Sep2015, Vol. 50 Issue 9, p1150
Academic Journal
The source of hematopoietic stem cells (HSCs) for allogeneic transplantation has evolved over the last decades, from the sole use of unstimulated bone marrow (BM) to the use of G-CSF (filgrastim)-mobilized peripheral blood, G-CSF-primed BM (G-BM) and cord blood. G-CSF-mobilized PBSC has replaced BM as the most commonly used source of allogeneic stem cells. G-BM is a source of HSCs, with studies demonstrating the safety and feasibility of this strategy with the potential for reducing GvHD, while retaining the speed of engraftment. Although the G-BM had lost its use as the optimal source of stem cells, after the widespread use of haploidentical transplantation, their use has resurfaced in 2010. This source can still be used in today's world of transplantation in aplastic anemia and other benign diseases, as well as in children donors. This study intends to review the evidence for this approach and whether this approach still has merit in the ever-evolving field of allogenic HSC transplantation. The merit of G-BM is its ability to offer speed of engraftment with reduced GvHD.


Related Articles

  • Hematopoietic stem cell transplantation using umbilical cord blood progenitors: review of current clinical results. Benito, A. I.; Diaz, M. A.; Gonz├ílez-Vicent, M.; Sevilla, J.; Madero, L. // Bone Marrow Transplantation;Apr2004, Vol. 33 Issue 7, p675 

    Summary:Umbilical cord blood (CB) has been rapidly established as an alternative source of stem cells to bone marrow for allogeneic-related and unrelated hematopoietic transplantation. To date, almost 70?000 CB units are available for transplantation and more than 2000 CB transplants (CBT) have...

  • Quantitative lymphocyte subset reconstitution after allogeneic hematopoietic transplantation from matched related donors with CD34+ selected PBPC grafts, unselected PBPC grafts or BM grafts. Behringer, D; Bertz, H; Schmoor, C; Berger, C; Dwenger, A; Finke, J // Bone Marrow Transplantation;8/1/99, Vol. 24 Issue 3, p295 

    CD34+ cell selection of PBPC after harvest from G-CSF-treated allogeneic donors results in a more than 200-fold depletion of T lymphocytes in the graft and has been used to reduce the incidence of acute GVHD post transplant. Since transplantation with T cell-depleted BM grafts is associated with...

  • Stem cell source-dependent reconstitution of FOXP3+ T cells after pediatric SCT and the association with allo-reactive disease. Reubsaet, L L; de Pagter, A P J; van Baarle, D; Keukens, L; Nanlohy, N; Sanders, E A M; Prakken, B J; Boelens, J J; de Kleer, I M // Bone Marrow Transplantation;Apr2013, Vol. 48 Issue 4, p502 

    In adult patients, regulatory CD4+FOXP3+ T cells are suggested to have a role in the control of allo-reactive disease after hematopoietic SCT (HSCT). We compared CD4+FOXP3+ T-cell reconstitution after unrelated cord blood (UCB), matched unrelated donor (MUD) and matched sibling donor (MSD) HSCT...

  • Devices for Umbilical Cord Blood Collection. Tan, Kok K.; Tang, Kok Z.; Sunan Huang // Recent Patents on Engineering;Feb2007, Vol. 1 Issue 1, p89 

    Umbilical cord blood (UCB) is an increasingly important and rich source of stem cells. These cells can be used for the treatment of many deadly diseases, including cancers, immune and genetic disorders. It also provides a readily available source of stem cells for transplantation purposes. In...

  • A strategy for enhancing the engraftment of human hematopoietic stem cells in NOD/SCID mice. Lee, Soo Hyun; Kim, Dae Seong; Lee, Myoung Woo; Noh, Yoo Hun; Jang, In Keun; Kim, Dong Hyun; Yang, Heung-Mo; Kim, Sung-Joo; Choi, Soo Jin; Oh, Wonil; Yang, Yoon Sun; Chueh, Hee Won; Son, Meong Hi; Jung, Hye Lim; Yoo, Keon Hee; Sung, Ki Woong; Koo, Hong Hoe // Annals of Hematology;Dec2013, Vol. 92 Issue 12, p1595 

    To overcome the limitations of allogeneic hematopoietic stem cell transplantation (HSCT), we conducted a study to identify a strategy for enhancing hematopoietic stem cell (HSC) engraftment during HSCT. Co-transplantation experiments with mesenchymal stem cells (MSCs) derived from adult human...

  • Changes in incidence and causes of non-relapse mortality after allogeneic hematopoietic cell transplantation in patients with acute leukemia/myelodysplastic syndrome: an analysis of the Japan Transplant Outcome Registry. Kurosawa, S; Yakushijin, K; Yamaguchi, T; Atsuta, Y; Nagamura-Inoue, T; Akiyama, H; Taniguchi, S; Miyamura, K; Takahashi, S; Eto, T; Ogawa, H; Kurokawa, M; Tanaka, J; Kawa, K; Kato, K; Suzuki, R; Morishima, Y; Sakamaki, H; Fukuda, T // Bone Marrow Transplantation;Apr2013, Vol. 48 Issue 4, p529 

    The outcomes for allogeneic hematopoietic cell transplantation (allo-HCT) are heavily influenced by non-relapse mortality (NRM). We retrospectively assessed the changes in the incidence and causes of NRM after allo-HCT over the past 12 years. NRM, relapse rate and OS were analyzed using the...

  • Hematopoietic Stem Cell Transplantation for Thalassemia. Gaziev, Javid; Lucarelli, Guido // Current Stem Cell Research & Therapy;Jun2011, Vol. 6 Issue 2, p162 

    Hematopoietic stem cell transplantation (HSCT) represents the only cure for patients with thalassemia. At present, HSCT in younger patients from an HLA- matched sibling donor offers 80% to 87% probability of cure according to risk classes. However, results of HSCT in adult patients continue to...

  • Stem cell transplant: An experience from eastern India. Mukhopadhyay, A.; Gupta, P.; Basak, J.; Chakraborty, A.; Bhattacharyya, D.; Mukhopadhyay, S.; Roy, U. K. // Indian Journal of Medical & Paediatric Oncology;Oct-Dec2012, Vol. 33 Issue 4, p203 

    Background: Hematopoietic stem cell transplant using human leukocyte antigen (HLA)- matched sibling or unrelated bone marrow, or related or unrelated cord blood has been performed successfully to treat patients with different types of hematological malignancies, genetic disorders and hereditary...

  • Long-term outcomes after allogeneic hematopoietic stem cell transplantation for metachromatic leukodystrophy: the largest single-institution cohort report. Boucher, Alexander A.; Miller, Weston; Shanley, Ryan; Ziegler, Richard; Lund, Troy; Raymond, Gerald; Orchard, Paul J. // Orphanet Journal of Rare Diseases;Aug2015, Vol. 10 Issue 1, p1 

    Background: Metachromatic Leukodystrophy (MLD) is a rare, fatal demyelinating disorder with limited treatment options. Published outcomes after hematopoietic stem cell transplantation (HSCT) are scant and mixed. We report survival and function following HSCT for a large, single-center MLD...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics